Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:temple
|
| gptkbp:affects |
metabolic syndrome
cardiovascular issues movement disorders hyperlipidemia diabetes risk |
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:brand |
quetiapine fumarate
|
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
NC T00027300
NC T00027400 NC T00027500 NC T00027600 NC T00027700 |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to quetiapine |
| gptkbp:dosage_form |
extended-release
immediate-release 150-300 mg/day for depression 300-600 mg/day for bipolar disorder 400-800 mg/day |
| gptkbp:form |
gptkb:tablet
extended-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Seroquel
|
| gptkbp:ingredients |
gptkb:quetiapine
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder treatment of major depressive disorder |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:temple
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:United_Kingdom gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:scholarships |
avoid alcohol
monitor blood sugar levels do not stop abruptly consult doctor before use in pregnancy monitor weight regularly |
| gptkbp:side_effect |
dizziness
drowsiness constipation dry mouth weight gain |
| gptkbp:symptoms |
anxiety
nausea irritability insomnia mood swings |